Noelia Tarazona, Research Fellow at Mass General Brigham Cancer Center, shared on LinkedIn:
“AFTER adding DYNAMIC III – When used at a single postoperative timepoint, tumor-informed and tumor-agnostic ctDNA assays show similar performance; however, with serial monitoring, tumor-informed assays clearly outperform tumor-agnostic approaches in sensitivity for recurrence detection!
This work moves beyond survival associations and focuses on what truly matters in daily practice: diagnostic accuracy, developed by our expert biostatistics Juan Antonio Carbonell Asins.
The study is the result of a strong international collaboration with the Mass General Brigham, together with leading experts in ctDNA and CRC Aparna Parikh, Leon Pappas.”
Title: Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis
Authors: Daniel G. Camblora, Belén Martínez-Castedo, Jorge Martín-Arana, Francisco Gimeno-Valiente, Blanca García-Micó, Francisco Martínez-Picó, Víctor Seguí, Miguel García-Bartolomé, Diego González, Alejandro Guimera, Marisol Huerta, Susana Roselló, Valentina Gambardella, Desamparados Roda, Leontios Pappas, Aparna Parikh, Juan Antonio Carbonell-Asins, Andrés Cervantes, Noelia Tarazona
You can read the full article in Cancer Treatment Reviews.
More posts featuring Noelia Tarazona.